• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

二价嵌合病毒样颗粒和 DNA 疫苗共免疫诱导小鼠产生有前景的体液免疫应答。

Co-Immunization With CHIKV VLP and DNA Vaccines Induces a Promising Humoral Response in Mice.

机构信息

National Health Commission (NHC) Key Laboratory of Medical Virology, National Institute for Viral Disease Control and Prevention, China CDC, Beijing, China.

Key Laboratory of Laboratory Medicine, Ministry of Education, School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Zhejiang, China.

出版信息

Front Immunol. 2021 Mar 24;12:655743. doi: 10.3389/fimmu.2021.655743. eCollection 2021.

DOI:10.3389/fimmu.2021.655743
PMID:33868299
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8044884/
Abstract

Chikungunya fever is an acute infectious disease that is mediated by the mosquito-transmitted chikungunya virus (CHIKV), for which no licensed vaccines are currently available. Here, we explored several immunization protocols and investigated their immunity and protective effects in mice, with DNA- and virus-like particle (VLP)- vaccines, both alone and in combination. Both DNA and VLP vaccine candidates were developed and characterized, which express CHIKV structural genes (C-E3-E2-6K-E1). Mice were immunized twice, with different protocols, followed by immunological detection and CHIKV Ross challenge. The highest antigen-specific IgG and neutralizing activity were induced by DNA and VLP co-immunization, while the highest cellular immunity was induced by DNA vaccination alone. Although all vaccine groups could protect mice from lethal CHIKV challenge, demonstrated as reduced viral load in various tissues, without weight loss, mice co-immunized with DNA and VLP exhibited the mildest histopathological changes and lowest International Harmonization of Nomenclature and Diagnostic Criteria (INHAND) scores, in comparison to mice with either DNA or VLP vaccination alone. We concluded that co-immunization with DNA and VLP is a promising strategy to inducing better protective immunity against CHIKV infection.

摘要

基孔肯雅热是一种由蚊媒传播的基孔肯雅病毒(CHIKV)引起的急性传染病,目前尚无许可的疫苗。在这里,我们探索了几种免疫方案,并在小鼠中研究了它们的免疫原性和保护作用,包括 DNA 疫苗和病毒样颗粒(VLP)疫苗,以及单独使用和联合使用。我们开发并表征了表达 CHIKV 结构基因(C-E3-E2-6K-E1)的 DNA 和 VLP 疫苗候选物。小鼠接受了两次免疫,采用不同的方案,然后进行免疫学检测和 CHIKV Ross 挑战。DNA 和 VLP 联合免疫诱导了最高的抗原特异性 IgG 和中和活性,而单独的 DNA 疫苗接种诱导了最高的细胞免疫。虽然所有疫苗组都能保护小鼠免受致死性 CHIKV 挑战,表现为各种组织中的病毒载量降低,体重无减轻,但与单独使用 DNA 或 VLP 疫苗接种的小鼠相比,DNA 和 VLP 联合免疫的小鼠表现出最轻微的组织病理学变化和最低的国际命名和诊断标准(INHAND)评分。我们得出结论,DNA 和 VLP 的联合免疫是诱导针对 CHIKV 感染更好保护免疫的一种有前途的策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/520d/8044884/f6a4b8fc2ac7/fimmu-12-655743-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/520d/8044884/2f80b3440819/fimmu-12-655743-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/520d/8044884/e39c26e334e3/fimmu-12-655743-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/520d/8044884/2c5ed0202766/fimmu-12-655743-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/520d/8044884/0db3f850c6de/fimmu-12-655743-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/520d/8044884/4d6398c44ce7/fimmu-12-655743-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/520d/8044884/f6a4b8fc2ac7/fimmu-12-655743-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/520d/8044884/2f80b3440819/fimmu-12-655743-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/520d/8044884/e39c26e334e3/fimmu-12-655743-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/520d/8044884/2c5ed0202766/fimmu-12-655743-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/520d/8044884/0db3f850c6de/fimmu-12-655743-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/520d/8044884/4d6398c44ce7/fimmu-12-655743-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/520d/8044884/f6a4b8fc2ac7/fimmu-12-655743-g006.jpg

相似文献

1
Co-Immunization With CHIKV VLP and DNA Vaccines Induces a Promising Humoral Response in Mice.二价嵌合病毒样颗粒和 DNA 疫苗共免疫诱导小鼠产生有前景的体液免疫应答。
Front Immunol. 2021 Mar 24;12:655743. doi: 10.3389/fimmu.2021.655743. eCollection 2021.
2
Vaccination with a chikungunya virus-like particle vaccine exacerbates disease in aged mice.接种基孔肯雅病毒样颗粒疫苗会使老年小鼠的病情恶化。
PLoS Negl Trop Dis. 2019 Apr 26;13(4):e0007316. doi: 10.1371/journal.pntd.0007316. eCollection 2019 Apr.
3
Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits.与糖蛋白 E1 或 E2 亚单位相比,基孔肯雅病毒样颗粒在致死性 AG129 小鼠模型中具有更高的免疫原性。
Vaccine. 2013 Dec 9;31(51):6092-6. doi: 10.1016/j.vaccine.2013.09.045. Epub 2013 Oct 5.
4
Prime-boost immunization strategies against Chikungunya virus.针对基孔肯雅病毒的初免-加强免疫策略。
J Virol. 2014 Nov;88(22):13333-43. doi: 10.1128/JVI.01926-14. Epub 2014 Sep 10.
5
Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial.一种基孔肯雅病毒样颗粒疫苗的安全性和耐受性结果:一项随机临床试验。
JAMA. 2020 Apr 14;323(14):1369-1377. doi: 10.1001/jama.2020.2477.
6
Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus.基孔肯雅病毒的全灭活疫苗和病毒样颗粒疫苗策略
J Infect Dis. 2016 Dec 15;214(suppl 5):S497-S499. doi: 10.1093/infdis/jiw352.
7
Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice.新型减毒基孔肯雅病毒疫苗候选株在C57BL/6小鼠中引发保护性免疫。
J Virol. 2014 Mar;88(5):2858-66. doi: 10.1128/JVI.03453-13. Epub 2013 Dec 26.
8
A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes.一种病毒样颗粒疫苗在人体内引发针对所有基孔肯雅病毒基因型的广泛中和抗体反应。
J Infect Dis. 2016 Nov 15;214(10):1487-1491. doi: 10.1093/infdis/jiw431. Epub 2016 Sep 21.
9
Development of Virus-Like-Particle Vaccine and Reporter Assay for Zika Virus.寨卡病毒样颗粒疫苗及报告基因检测法的研发
J Virol. 2017 Sep 27;91(20). doi: 10.1128/JVI.00834-17. Print 2017 Oct 15.
10
A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates.一种基孔肯雅病毒的 DNA 疫苗可在小鼠中起到保护作用,并在小鼠和非人灵长类动物中诱导产生中和抗体。
PLoS Negl Trop Dis. 2011 Jan 11;5(1):e928. doi: 10.1371/journal.pntd.0000928.

引用本文的文献

1
Humoral and cellular immune response to a single dose of a novel bivalent recombinant adenovirus-vector vaccine against West Nile virus and chikungunya virus in mice.小鼠对单剂量新型二价重组腺病毒载体西尼罗河病毒和基孔肯雅病毒疫苗的体液免疫和细胞免疫反应
Virol J. 2025 Jul 25;22(1):256. doi: 10.1186/s12985-025-02878-5.
2
Pathogenesis and clinical management of arboviral diseases.虫媒病毒病的发病机制与临床管理
World J Virol. 2025 Mar 25;14(1):100489. doi: 10.5501/wjv.v14.i1.100489.
3
Robust and Long-Lasting Immunity and Protection in Mice Induced by Lipopolyplex-Delivered mRNA Vaccines Expressing the Prefusion Protein of Respiratory Syncytial Virus.

本文引用的文献

1
A single-dose live-attenuated YF17D-vectored SARS-CoV-2 vaccine candidate.一种单价减毒 YF17D 载体 SARS-CoV-2 疫苗候选物。
Nature. 2021 Feb;590(7845):320-325. doi: 10.1038/s41586-020-3035-9. Epub 2020 Dec 1.
2
Recent advances in therapeutic applications of neutralizing antibodies for virus infections: an overview.病毒感染治疗应用中中和抗体的最新进展:概述。
Immunol Res. 2020 Dec;68(6):325-339. doi: 10.1007/s12026-020-09159-z. Epub 2020 Nov 8.
3
Recent Progress in Vaccine Development Against Chikungunya Virus.抗基孔肯雅病毒疫苗研发的最新进展
表达呼吸道合胞病毒融合前蛋白的脂质多聚体递送mRNA疫苗在小鼠中诱导产生强大且持久的免疫和保护作用。
Vaccines (Basel). 2025 Jan 20;13(1):93. doi: 10.3390/vaccines13010093.
4
A Comprehensive Review of mRNA-based Vaccines for COVID-19, A New Era in Pharmaceuticals: Unspecified and Unknown Aspects, Effects and Challenges.新型冠状病毒肺炎mRNA疫苗综合综述:制药新时代的未明确及未知方面、影响与挑战
Curr Top Med Chem. 2025;25(12):1467-1491. doi: 10.2174/0115680266325847241121034100.
5
A single dose recombinant AAV based CHIKV vaccine elicits robust and durable protective antibody responses in mice.单次剂量重组 AAV 基 CHIKV 疫苗在小鼠中引发强烈和持久的保护性抗体反应。
PLoS Negl Trop Dis. 2024 Nov 4;18(11):e0012604. doi: 10.1371/journal.pntd.0012604. eCollection 2024 Nov.
6
The PCV3 Cap Virus-like Particle Vaccine with the Chimeric PCV2-Neutralizing Epitope Gene Is Effective in Mice.具有嵌合PCV2中和表位基因的PCV3 Cap病毒样颗粒疫苗对小鼠有效。
Vet Sci. 2024 Jun 8;11(6):264. doi: 10.3390/vetsci11060264.
7
Development of a novel virus-like particle-based vaccine for preventing tick-borne encephalitis virus infection.开发一种新型基于病毒样颗粒的疫苗,用于预防蜱传脑炎病毒感染。
Virol Sin. 2023 Oct;38(5):767-777. doi: 10.1016/j.virs.2023.06.003. Epub 2023 Jun 14.
8
Vaccine development for mosquito-borne viral diseases.蚊媒病毒病疫苗的研发。
Front Immunol. 2023 May 12;14:1161149. doi: 10.3389/fimmu.2023.1161149. eCollection 2023.
9
mRNA-Based Vaccine for COVID-19: They Are New but Not Unknown!基于mRNA的新冠疫苗:它们虽新但并非未知!
Vaccines (Basel). 2023 Feb 22;11(3):507. doi: 10.3390/vaccines11030507.
10
Synergistic Immunity and Protection in Mice by Co-Immunization with DNA Vaccines Encoding the Spike Protein and Other Structural Proteins of SARS-CoV-2.通过联合免疫编码严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白和其他结构蛋白的DNA疫苗在小鼠中产生的协同免疫和保护作用。
Vaccines (Basel). 2023 Jan 21;11(2):243. doi: 10.3390/vaccines11020243.
Front Microbiol. 2019 Dec 19;10:2881. doi: 10.3389/fmicb.2019.02881. eCollection 2019.
4
Antiviral drug discovery against arthritogenic alphaviruses: Tools and molecular targets.抗关节炎甲病毒的抗病毒药物研发:工具和分子靶标。
Biochem Pharmacol. 2020 Apr;174:113777. doi: 10.1016/j.bcp.2019.113777. Epub 2019 Dec 23.
5
Infectious Chikungunya Virus (CHIKV) with a Complete Capsid Deletion: a New Approach for a CHIKV Vaccine.具有完整衣壳缺失的感染性基孔肯雅病毒(CHIKV):一种新型的基孔肯雅病毒疫苗。
J Virol. 2019 Jul 17;93(15). doi: 10.1128/JVI.00504-19. Print 2019 Aug 1.
6
Vaccination with a chikungunya virus-like particle vaccine exacerbates disease in aged mice.接种基孔肯雅病毒样颗粒疫苗会使老年小鼠的病情恶化。
PLoS Negl Trop Dis. 2019 Apr 26;13(4):e0007316. doi: 10.1371/journal.pntd.0007316. eCollection 2019 Apr.
7
Humoral and cellular immunity against both ZIKV and poxvirus is elicited by a two-dose regimen using DNA and non-replicating vaccinia virus-based vaccine candidates.使用基于DNA和非复制型痘苗病毒的候选疫苗进行两剂接种方案,可引发针对寨卡病毒和痘病毒的体液免疫和细胞免疫。
Vaccine. 2019 Apr 3;37(15):2122-2130. doi: 10.1016/j.vaccine.2019.02.063. Epub 2019 Mar 6.
8
51 years in of Chikungunya clinical vaccine development: A historical perspective.基孔肯雅热临床疫苗研发 51 年:历史视角。
Hum Vaccin Immunother. 2019;15(10):2351-2358. doi: 10.1080/21645515.2019.1574149. Epub 2019 Apr 2.
9
Attenuation and Stability of CHIKV-NoLS, a Live-Attenuated Chikungunya Virus Vaccine Candidate.基孔肯雅病毒减毒活疫苗候选株CHIKV-NoLS的减毒作用及稳定性
Vaccines (Basel). 2018 Dec 22;7(1):2. doi: 10.3390/vaccines7010002.
10
Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial.基于麻疹病毒的基孔肯雅病毒疫苗 MV-CHIK 的免疫原性、安全性和耐受性:一项双盲、随机、安慰剂对照和阳性对照的 2 期临床试验。
Lancet. 2019 Dec 22;392(10165):2718-2727. doi: 10.1016/S0140-6736(18)32488-7. Epub 2018 Nov 5.